Loading...
•
Dec 31, 2020
Heron Therapeutics Q4 2020 Earnings Report
Heron Therapeutics' financial results for Q4 2020 were announced, highlighting corporate updates and exceeding CINV sales guidance despite challenges.
Key Takeaways
Heron Therapeutics reported net product sales of $20.6 million for the quarter ended December 31, 2020, and a net loss of $62.3 million, or $0.68 per share. The company ended the year with $208.5 million in cash, cash equivalents, and short-term investments. They anticipate a transformational year in 2021 with growth in CINV products and the potential approval and launch of HTX-011.
Net product sales for Q4 2020 were $20.6 million, compared to $35.1 million for the same period in 2019.
Net loss for Q4 2020 was $62.3 million, or $0.68 per share, compared to $57.9 million, or $0.65 per share, for the same period in 2019.
CINV franchise net product sales were $20.6 million for Q4 2020, compared to $35.1 million for the same period in 2019.
Heron ended 2020 with $208.5 million in cash, cash equivalents and short-term investments.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.com Forward Guidance
Heron expects full-year 2021 net product sales for the CINV franchise of $130 million to $145 million.